"Disease-Free Survival" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
| Descriptor ID |
D018572
|
| MeSH Number(s) |
E01.789.200 E05.318.740.998.300 N05.715.360.750.795.300 N06.850.520.830.998.300
|
| Concept/Terms |
Disease-Free Survival- Disease-Free Survival
- Disease Free Survival
- Event-Free Survival
- Event Free Survival
- Event-Free Survivals
- Survival, Event-Free
- Survivals, Event-Free
- Survival, Disease-Free
- Disease-Free Survivals
- Survival, Disease Free
- Survivals, Disease-Free
Progression-Free Survival- Progression-Free Survival
- Progression Free Survival
- Progression-Free Survivals
- Survival, Progression-Free
- Survivals, Progression-Free
|
Below are MeSH descriptors whose meaning is more general than "Disease-Free Survival".
Below are MeSH descriptors whose meaning is more specific than "Disease-Free Survival".
This graph shows the total number of publications written about "Disease-Free Survival" by people in this website by year, and whether "Disease-Free Survival" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 6 | 6 |
| 1997 | 0 | 6 | 6 |
| 1998 | 0 | 11 | 11 |
| 1999 | 0 | 5 | 5 |
| 2000 | 0 | 10 | 10 |
| 2001 | 0 | 13 | 13 |
| 2002 | 0 | 6 | 6 |
| 2003 | 0 | 14 | 14 |
| 2004 | 0 | 19 | 19 |
| 2005 | 0 | 11 | 11 |
| 2006 | 0 | 14 | 14 |
| 2007 | 0 | 20 | 20 |
| 2008 | 0 | 32 | 32 |
| 2009 | 0 | 25 | 25 |
| 2010 | 0 | 25 | 25 |
| 2011 | 0 | 33 | 33 |
| 2012 | 1 | 35 | 36 |
| 2013 | 0 | 39 | 39 |
| 2014 | 0 | 48 | 48 |
| 2015 | 0 | 52 | 52 |
| 2016 | 0 | 61 | 61 |
| 2017 | 0 | 60 | 60 |
| 2018 | 1 | 43 | 44 |
| 2019 | 0 | 34 | 34 |
| 2020 | 0 | 26 | 26 |
| 2021 | 0 | 10 | 10 |
| 2022 | 0 | 6 | 6 |
| 2023 | 0 | 9 | 9 |
| 2024 | 0 | 10 | 10 |
| 2025 | 0 | 2 | 2 |
| 2026 | 0 | 6 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Disease-Free Survival" by people in Profiles.
-
Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. Cancer. 2022 08 01; 128(15):2967-2977.
-
Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review. PLoS One. 2021; 16(4):e0250057.
-
A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation. Blood. 2021 02 18; 137(7):983-993.
-
The importance of age as prognostic factor for the outcome of patients with hepatoblastoma: Analysis from the Children's Hepatic tumors International Collaboration (CHIC) database. Pediatr Blood Cancer. 2020 08; 67(8):e28350.
-
Ancestry and frequency of genetic variants in the general population are confounders in the characterization of germline variants linked to cancer. BMC Med Genet. 2020 05 06; 21(1):92.
-
Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy. Br J Haematol. 2020 06; 189(6):1171-1181.
-
Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab. Oncologist. 2020 06; 25(6):e909-e919.
-
Outcomes of Liver Transplantation for Hepatocellular Carcinoma Beyond the University of California San Francisco Criteria: A Single-center Experience. Transplantation. 2020 01; 104(1):113-121.
-
Survival disparities for second primary malignancies diagnosed among childhood cancer survivors: A population-based assessment. Cancer. 2019 10 15; 125(20):3623-3630.
-
Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura. Blood Adv. 2019 05 14; 3(9):1512-1518.